Pluri Inc. PLUR
Pluri Inc. (Nasdaq: PLUR) is a drug developer. Its lead program, PLX cell therapy (placental-derived adherent stromal cells), is in Pre-clinical.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PLX cells (adherent stromal cell product candidates) | — | cell therapy | Pre-clinical |
| Engineered placental MAIT cells | — | cell therapy | Pre-clinical |
Recent results and decisions
- Oct 19, 2026n/a Pluri Inc. closed $1.25 million registered direct offering with issuance of 833,334 common shares at $1.50 per share and warrants to purchase 833,334 shares at $1.65 exercise price.
The Company agreed to issue and sell to the Purchaser (i) 833,334 common shares of the Company, par value $0.00001 per share, at a purchase price of $1.50 per Share and (ii) a common shares purchase warrant to purchase up to 833,334 common shares of the Company at an exercise price of $1.65 per Warr
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.